The US Food and Drug Administration approves the first effective treatment for “vitiligo”

The health authorities in the United States announced a revolutionary treatment for vitiligo in adults and children, which may be the first of its kind to treat this disease that affects millions globally.
According to the newspaper “Daily Mail”, the US Food and Drug Administration granted approval to the “Opzelura” cream, which was developed by the American company “Wilmington”, as a topical treatment for vitiligo in adults and children aged 12 years and over.
With this great scientific development, “Opzelura” cream became the first treatment for re-pigmentation of the skin of patients with vitiligo to receive approval by the Food and Drug Administration.
The new cream is approved to be used topically and continuously on non-pigmented patches of skin, twice a day, and should not be used on more than 10 percent of the body’s surface area.
The company noted that the patient’s response to treatment may require the use of “Opzelura” cream for more than 24 weeks.
Experiments have been conducted on more than 600 people with non-articular vitiligo, aged 12 years or older.
According to the results at week 24, approximately 30% of the people who received the new cream achieved an improvement in their skin color of at least 75% in the areas of vitiligo.
“We are delighted that vitiligo patients now have the option to treat re-pigmentation,” said Insights CEO Herve Hopinot.
According to estimates, vitiligo affects 1 to 2 percent of the world’s population, and it is not a fatal or contagious disease.